Adtran builds on 30-year legacy of US telecommunications equipment manufacturing through strategic investment to support historic high-speed internet deployment
16.8.2023 19:00:00 EEST | Business Wire | Press release
Adtran today announced the expansion of advanced telecommunications equipment manufacturing at its state-of-the-art facility in Huntsville, Alabama, to meet the growing demand for domestically produced network electronics, spurred by the Biden-Harris Administration’s $42.45 billion Broadband Equity, Access and Deployment (BEAD) Program and its Made-in-America policies in the Bipartisan Infrastructure Law.
With a total investment of up to $5 million and the creation of up to 300 high-quality, good-paying jobs, today’s announcement is an exciting step forward in Adtran’s decades-long journey to make communications simpler and more affordable for millions of Americans.
Adtran is expanding its current US production of optical line termination (OLT) equipment and preparing to onshore the manufacturing of optical network terminals (ONTs).
To celebrate this announcement, Adtran is welcoming Mitch Landrieu, Senior Advisor to the President and White House Infrastructure Coordinator, and Alan Davidson, Assistant Secretary of Commerce for Communications and Information and NTIA Administrator, for a tour of its 270,000-square-foot manufacturing facility.
“As a leading US telecommunications equipment provider, we look forward to partnering with state broadband offices and network operators across the country as they expand secure, high-speed internet access to millions of Americans,” said Tom Stanton, CEO of Adtran. “This expansion not only represents a strategic investment in Adtran’s growing workforce and manufacturing capabilities but also demonstrates our long-term commitment to strengthening the domestic supply chain and securing communications networks with American-made equipment.”
Adtran is excited to welcome new employees to its team and is committed to investing in their success with on-the-job training and by extending the same industry-leading benefits it offers its current employees, including a college tuition reimbursement program.
Adtran is investing in the community by partnering with local area schools for its high school apprenticeship program and developing a co-op program for college students. The diversity of Adtran’s workforce reflects the diversity of Alabama: People of color make up over 40% of Adtran’s manufacturing team and one-third identify as African American. 57% of manufacturing employees are women, compared to a manufacturing industry average of just 30%.
“This announcement is the latest example of how we’re turning ‘Made in America’ into a reality and expanding manufacturing across the country,” commented Gina Raimondo, US Secretary of Commerce. “Thanks to President Biden’s Investing in America agenda, we will connect everyone in America to high-speed internet networks built by American workers with American-made equipment.”
“The Internet for All initiative is not just a connectivity program, it’s a jobs program – for the people who build the networks and for the people who make the equipment those networks need,” said Alan Davidson, Assistant Secretary of Commerce for Communications and Information and NTIA Administrator. “If network equipment can be made in America, it should be made in America. Companies like Adtran are stepping up and answering that call.”
“Access to high-speed internet is no longer a luxury – it is an essential tool to access education, healthcare and jobs,” commented Mitch Landrieu, Senior Advisor to the President and White House Infrastructure Coordinator. “President Biden’s Investing in America agenda has made the largest investment in high-speed internet in our country’s history to ensure all Americans are connected to affordable, reliable high-speed internet using Made-in-America materials. Adtran’s exciting announcement today is part of a manufacturing boom that is creating good-paying jobs and boosting our economy – including here in Huntsville, Alabama.”
“The Tennessee Valley has long been a national leader in developing the advanced technologies that support our modern industrial base. The investments announced today will help ensure that broadband is able to reach more Americans with equipment made right here in North Alabama, supporting our economy and the United States as a whole,” noted Dale Strong, US Representative (AL-05).
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230816701452/en/
Contact information
For media
Rob Snyder
+1 256 963 6383
public-relations@adva.com
For investors
Steven Williams
+49 89 890 665 918
investor@adtran.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
